These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16181820)

  • 1. Cardioprotection: a new paradigm in the management of acute heart failure syndromes.
    Maytin M; Colucci WS
    Am J Cardiol; 2005 Sep; 96(6A):26G-31G. PubMed ID: 16181820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cardioprotective effects of levosimendan: preclinical and clinical evidence.
    Pollesello P; Papp Z
    J Cardiovasc Pharmacol; 2007 Sep; 50(3):257-63. PubMed ID: 17878752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized clinical trials with levosimendan.
    Mebazaa A; Barraud D; Welschbillig S
    Am J Cardiol; 2005 Sep; 96(6A):74G-9G. PubMed ID: 16181826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of levosimendan on the energy balance: preclinical and clinical evidence.
    Nieminen MS; Pollesello P; Vajda G; Papp Z
    J Cardiovasc Pharmacol; 2009 Apr; 53(4):302-10. PubMed ID: 19276987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical experience with levosimendan in anesthesiology and in the intensive care unit.
    Cavana M; Pignataro C; Fraticelli A; Mebazaa A
    Ital Heart J; 2003 May; 4 Suppl 2():61S-64S. PubMed ID: 14635372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of new agents for acute heart failure syndromes.
    Gheorghiade M; Teerlink JR; Mebazaa A
    Am J Cardiol; 2005 Sep; 96(6A):68G-73G. PubMed ID: 16181825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.
    Pathak A; Lebrin M; Vaccaro A; Senard JM; Despas F
    J Clin Pharm Ther; 2013 Oct; 38(5):341-9. PubMed ID: 23594161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-based use of levosimendan in different clinical settings.
    De Luca L; Colucci WS; Nieminen MS; Massie BM; Gheorghiade M
    Eur Heart J; 2006 Aug; 27(16):1908-20. PubMed ID: 16682381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European experience on the practical use of levosimendan in patients with acute heart failure syndromes.
    Follath F; Franco F; Cardoso JS
    Am J Cardiol; 2005 Sep; 96(6A):80G-5G. PubMed ID: 16181827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of levosimendan in the treatment of heart failure.
    Lehtonen L; Põder P
    Ann Med; 2007; 39(1):2-17. PubMed ID: 17364447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levosimendan: dual mechanisms for acute heart failure...and beyond?
    Ng TM; Akhter MW
    Minerva Cardioangiol; 2005 Dec; 53(6):565-84. PubMed ID: 16333239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levosimendan: implications for clinicians.
    McBride BF; White CM
    J Clin Pharmacol; 2003 Oct; 43(10):1071-81. PubMed ID: 14517189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of levosimendan in acute heart failure and its effect on renal function].
    Moyano AP; Hidalgo RL; Grande DB; Morales SC
    Nefrologia; 2009; 29(6):616-7. PubMed ID: 19936016
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel biologic mechanisms of levosimendan and its effect on the failing heart.
    Parissis JT; Andreadou I; Bistola V; Paraskevaidis I; Filippatos G; Kremastinos DT
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1143-50. PubMed ID: 18616411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levosimendan: a new option in acute cardiac failure.
    Holley AD; Ziegenfuss M
    Emerg Med Australas; 2006; 18(5-6):505-9. PubMed ID: 17083641
    [No Abstract]   [Full Text] [Related]  

  • 17. Is calcium sensitization the best strategy to improve myocardial contractility in acute heart failure?
    Erhardt LR
    Ital Heart J; 2003 May; 4 Suppl 2():27S-33S. PubMed ID: 14635367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New pharmacologic options in the treatment of acute coronary syndromes and myocardial ischemia-reperfusion injury: potential role of levosimendan.
    Garcia-Gonzalez MJ; Dominguez-Rodriguez A; Abreu-Gonzalez P
    Minerva Cardioangiol; 2007 Oct; 55(5):625-35. PubMed ID: 17912166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure.
    Perrone SV; Kaplinsky EJ
    Int J Cardiol; 2005 Sep; 103(3):248-55. PubMed ID: 16098385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.